TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07424404: A Phase 3 Multicenter, Open-label Study to Assess the Long-term Safety and Tolerability of Xanomeline and Trospium Chloride in Children and Adolescents With Psychiatric Disorders

Sponsor: Karuna Therapeutics, Inc., a Bristol Myers Squibb company · Phase: PHASE3 · Area: CNS_NEUROLOGY · Target Enrollment: 400 pts

Competing Trials Overlap

11 Active Trials

Excess Burn Exposure

$3,305,760

Rescue Site Savings

+$2,203,840

Unlock Full NCT07424404 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07424404 Rescue Dossier →